Cigna earnings beat by $0.04, revenue topped estimates
Investing.com -- Imunon Inc (NASDAQ:IMNN) stock jumped 6.4% Monday after the clinical-stage biotechnology company announced it has dosed the first patient in its pivotal Phase 3 OVATION 3 Study.
The trial is evaluating IMNN-001, the company’s lead DNA-mediated immunotherapy candidate, for the treatment of women with newly diagnosed advanced ovarian cancer. The first patient was dosed at Providence Health in Spokane, Washington.
The Phase 3 study will assess the safety and efficacy of IMNN-001 administered intraperitoneally weekly plus standard neoadjuvant and adjuvant chemotherapy compared to standard chemotherapy alone. The trial’s primary endpoint is overall survival, with secondary endpoints including surgical response score and time to second-line treatment.
"Dosing the first patient is an important step forward and we expect to build on this momentum in the coming months as patient enrollment activities continue to accelerate in the OVATION 3 Study," said Stacy Lindborg, president and CEO of IMUNON.
The company previously reported positive data from its Phase 2 OVATION 2 Study at the American Society of Clinical Oncology Annual Meeting in June 2025. Those results showed that treatment with IMNN-001 plus standard chemotherapy resulted in clinically meaningful improvements in overall survival and progression-free survival with a favorable safety profile.
IMUNON also recently presented translational data demonstrating that IMNN-001 creates a "hot" anti-tumor microenvironment by recruiting immune cells to the tumor site, further validating the drug’s mechanism of action.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.